10:04 AM EST - IntelGenx Corp. : announced a partnership with Circ Pharma in which IntelGenx will formulate, manufacture and supply to Circ, while Circ will develop and commercialize a novel drug product for the treatment of hyperlipidemia. Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product's sales. IntelGenx will use its proprietary Versatab technology to formulate the product. The product is expected to reach the market in 2012. IntelGenx Corp.
shares V.IGX are trading even at $0.65.
